ATE333275T1 - Indole-3-propionsäure, ihre salze und ester als arzneimittel - Google Patents

Indole-3-propionsäure, ihre salze und ester als arzneimittel

Info

Publication number: ATE333275T1
Authority: AT; Austria
Prior art keywords: indole; propionic acid; ester; salt; effective amount
Prior art date: 1998-02-23

Application number

AT99908381T

Other languages

English (en)

Inventor

Miguel A Pappolla

Blas Frangione

Jorge Ghiso

Burkhard Poeggeler

Original Assignee

Univ South Alabama

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-23

Filing date

1999-02-23

Publication date

2006-08-15

1999-02-23 Application filed by Univ South Alabama, Univ New York filed Critical Univ South Alabama

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE333275T1 publication Critical patent/ATE333275T1/de

Links

GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 title abstract 10
239000003290 indole 3-propionic acid Substances 0.000 title abstract 5
229940126601 medicinal product Drugs 0.000 title 1
150000002148 esters Chemical class 0.000 abstract 4
150000003839 salts Chemical class 0.000 abstract 4
239000012472 biological sample Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000035557 fibrillogenesis Effects 0.000 abstract 1
230000002600 fibrillogenic effect Effects 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
230000036542 oxidative stress Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

AT99908381T 1998-02-23 1999-02-23 Indole-3-propionsäure, ihre salze und ester als arzneimittel ATE333275T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7555598P	1998-02-23	1998-02-23
US11256598P	1998-12-16	1998-12-16

Publications (1)

Publication Number	Publication Date
ATE333275T1 true ATE333275T1 (de)	2006-08-15

Family

ID=26757006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99908381T ATE333275T1 (de)	1998-02-23	1999-02-23	Indole-3-propionsäure, ihre salze und ester als arzneimittel

Country Status (17)

Country	Link
US (1)	US6395768B1 (de)
EP (1)	EP1056452B1 (de)
JP (2)	JP5627160B2 (de)
CN (1)	CN1147299C (de)
AT (1)	ATE333275T1 (de)
AU (1)	AU757925B2 (de)
BR (1)	BR9908165A (de)
CA (1)	CA2321455C (de)
DE (1)	DE69932414T2 (de)
DK (1)	DK1056452T3 (de)
EA (1)	EA005244B1 (de)
ES (1)	ES2270585T3 (de)
IL (2)	IL137848A0 (de)
MX (1)	MXPA00008216A (de)
NZ (1)	NZ506260A (de)
PT (1)	PT1056452E (de)
WO (1)	WO1999042102A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6719988B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Antiseptic compositions for inactivating prions
US6322802B1 (en)	1999-06-01	2001-11-27	The Regents Of The University Of California	Method of sterilizing
US6419916B1 (en)	1999-06-01	2002-07-16	The Regents Of The University Of California	Assay for compounds which affect conformationally altered proteins
US6720355B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Sodium dodecyl sulfate compositions for inactivating prions
DE10006139A1 (de) *	2000-02-11	2001-08-16	Merck Patent Gmbh	Indol-3-yl-Derivate
US7491699B2 (en)	2002-12-09	2009-02-17	Ramot At Tel Aviv University Ltd.	Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de)	2003-01-07	2009-04-15	Univ Ramot	Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US7348338B2 (en) *	2003-07-17	2008-03-25	Plexxikon, Inc.	PPAR active compounds
CA2532403A1 (en) *	2003-07-17	2005-02-03	James Arnold	Ppar active compounds
US7125861B2 (en) *	2003-07-31	2006-10-24	Rolland F Hebert	Water-soluble chitosan-indole-3-propionic acid conjugates
EP1663199B1 (de)	2003-09-25	2013-04-03	Tel Aviv University Future Technology Development L.P.	Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen
WO2005031362A2 (en)	2003-10-02	2005-04-07	Ramot At Tel Aviv University Ltd.	Novel antibacterial agents and methods of identifying and utilizing same
US20070105937A1 (en) *	2003-12-22	2007-05-10	Miguel Pappolla	Indole-3-propionamide and derivatives thereof
EP1781310B1 (de)	2004-08-02	2015-10-14	Ramot at Tel Aviv University Ltd.	Artikel von peptidnanostrukturen und herstellungsverfahren dafür
US7732479B2 (en)	2004-08-19	2010-06-08	Tel Aviv University Future Technology Development L.P.	Compositions for treating amyloid associated diseases
JP2008521831A (ja) *	2004-11-30	2008-06-26	プレキシコン，インコーポレーテッド	Ｐｐａｒ活性化合物
JP2008521829A (ja) *	2004-11-30	2008-06-26	プレキシコン，インコーポレーテッド	Ｐｐａｒ活性化合物
CA2609980C (en) *	2005-05-27	2015-10-13	Queen's University At Kingston	Treatment of protein folding disorders
BRPI0615948A2 (pt) *	2005-09-07	2011-05-31	Plexxikon Inc	composto ativo de ppar, sua composição, seu kit e seu uso
JP2009509932A (ja) *	2005-09-07	2009-03-12	プレキシコン，インコーポレーテッド	Ｐｐａｒ活性化合物
EP1973928A2 (de)	2005-10-11	2008-10-01	Ramot at Tel-Aviv University Ltd.	Selbstzusammengebaute fmoc-ff-hydrogele
WO2008024914A2 (en) *	2006-08-23	2008-02-28	Intellect Neurosciences Inc.	3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
PE20090159A1 (es) *	2007-03-08	2009-02-21	Plexxikon Inc	COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US9744155B2 (en)	2012-03-28	2017-08-29	Ixcela, Inc.	IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
HK1225760A1 (zh) *	2014-01-31	2017-09-15	Ixcela, Inc.	作为生物标记物的共价结合代谢物
CN108125950B (zh) *	2017-12-28	2020-09-25	崔明	吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2020083827A (ja) *	2018-11-27	2020-06-04	国立研究開発法人農業・食品産業技術総合研究機構	ケミカルシャペロンまたは神経細胞死の抑制剤
US11041847B1 (en)	2019-01-25	2021-06-22	Ixcela, Inc.	Detection and modification of gut microbial population
CN109674787A (zh) *	2019-02-01	2019-04-26	百迈康生物医药科技(广州)有限公司	一种防治缺血性心脏病的药物及其应用
CN109730993A (zh) *	2019-02-28	2019-05-10	北京大学人民医院(北京大学第二临床医学院)	吲哚丙酸在制备防治类风湿关节炎药物中的应用
WO2020185913A1 (en) *	2019-03-12	2020-09-17	Intellect Neurosciences, Inc.	Indole-3-propionic acids and salts and esters thereof for treating skin disorders
EP4076424A1 (de) *	2019-12-20	2022-10-26	Basf Se	Zusammensetzung für die behandlung von amyloid-beta-assoziierten krankheiten
CN118141804A (zh) *	2024-03-06	2024-06-07	浙江大学	吲哚-3-丙酸在制备用于增敏肿瘤免疫治疗的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536505A (en) *	1983-05-17	1985-08-20	Ciba-Geigy Corporation	Certain N-(pyridyl) indoles
JP2602735B2 (ja) *	1989-09-27	1997-04-23	株式会社大塚製薬工場	抗活性酸素剤
JPH0578248A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
JPH0578247A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
EP0613463A1 (de) *	1991-11-18	1994-09-07	G.D. Searle & Co.	Derivate von cyclischen phenolischen thioethern als inhibitoren oder stimulatoren der superoxid-erzeugung
WO1994003427A1 (en) *	1992-08-06	1994-02-17	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
JPH0881442A (ja) *	1994-07-14	1996-03-26	Otsuka Pharmaceut Co Ltd	環状アミド誘導体
HUT76923A (hu) *	1994-07-27	1998-01-28	Sankyo Company Limited	Muszkarinreceptorokra alloszterikus hatást kifejtő heterociklusos vegyületek
JPH08175993A (ja) *	1994-12-21	1996-07-09	Green Cross Corp:The	抗酸化剤
JPH09249567A (ja) *	1996-01-12	1997-09-22	Otsuka Pharmaceut Co Ltd	医薬組成物
TW430660B (en) *	1996-05-30	2001-04-21	Mochida Pharm Co Ltd	Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them

1999
- 1999-02-23 EP EP99908381A patent/EP1056452B1/de not_active Expired - Lifetime
- 1999-02-23 JP JP2000532118A patent/JP5627160B2/ja not_active Expired - Fee Related
- 1999-02-23 WO PCT/US1999/003906 patent/WO1999042102A1/en not_active Ceased
- 1999-02-23 EA EA200000874A patent/EA005244B1/ru not_active IP Right Cessation
- 1999-02-23 CA CA2321455A patent/CA2321455C/en not_active Expired - Lifetime
- 1999-02-23 PT PT99908381T patent/PT1056452E/pt unknown
- 1999-02-23 DK DK99908381T patent/DK1056452T3/da active
- 1999-02-23 ES ES99908381T patent/ES2270585T3/es not_active Expired - Lifetime
- 1999-02-23 MX MXPA00008216A patent/MXPA00008216A/es active IP Right Grant
- 1999-02-23 BR BR9908165-2A patent/BR9908165A/pt not_active Application Discontinuation
- 1999-02-23 DE DE69932414T patent/DE69932414T2/de not_active Expired - Lifetime
- 1999-02-23 IL IL13784899A patent/IL137848A0/xx unknown
- 1999-02-23 AT AT99908381T patent/ATE333275T1/de active
- 1999-02-23 AU AU27828/99A patent/AU757925B2/en not_active Ceased
- 1999-02-23 CN CNB998032441A patent/CN1147299C/zh not_active Expired - Fee Related
- 1999-02-23 NZ NZ506260A patent/NZ506260A/en not_active IP Right Cessation
2000
- 2000-05-30 US US09/580,437 patent/US6395768B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137848A patent/IL137848A/en not_active IP Right Cessation
2011
- 2011-10-20 JP JP2011230632A patent/JP2012017343A/ja active Pending

Also Published As

Publication number	Publication date
CN1292693A (zh)	2001-04-25
US6395768B1 (en)	2002-05-28
JP2012017343A (ja)	2012-01-26
DK1056452T3 (da)	2006-11-20
WO1999042102A1 (en)	1999-08-26
DE69932414D1 (de)	2006-08-31
AU2782899A (en)	1999-09-06
IL137848A0 (en)	2001-10-31
EA200000874A1 (ru)	2001-02-26
JP5627160B2 (ja)	2014-11-19
AU757925B2 (en)	2003-03-13
BR9908165A (pt)	2000-10-31
DE69932414T2 (de)	2007-02-22
MXPA00008216A (es)	2004-11-22
HK1036588A1 (en)	2002-01-11
EP1056452A1 (de)	2000-12-06
ES2270585T3 (es)	2007-04-01
PT1056452E (pt)	2006-12-29
EA005244B1 (ru)	2004-12-30
JP2002503691A (ja)	2002-02-05
CN1147299C (zh)	2004-04-28
EP1056452B1 (de)	2006-07-19
WO1999042102A8 (en)	2001-02-15
IL137848A (en)	2010-11-30
CA2321455A1 (en)	1999-08-26
CA2321455C (en)	2010-10-19
NZ506260A (en)	2003-05-30

Legal Events

Date

Code

Title

Description

2007-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1056452

Country of ref document: EP

Publication	Publication Date	Title
ATE333275T1 (de)	2006-08-15	Indole-3-propionsäure, ihre salze und ester als arzneimittel
DE69822832D1 (de)	2004-05-06	Therapeutische und lebensmittel-zusammensetzungen, welche essentielle fettsäuren und bioaktive disulfide enthalten
DE69004081D1 (de)	1993-11-25	Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
ATE267798T1 (de)	2004-06-15	Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
PT801649E (pt)	2002-12-31	Derivados de hidroxilamina uteis para aumentar a producao de proteinas moleculares adventicias e sua preparacao
NO157020C (no)	1988-01-06	Analogifremgangsmte ved fremstilling av terapeutisk aktive 3,20-dioxo-1,4-pregnadien-17alfa-ol-17-aromatiske heterocykliske carboxylater.
ES2171933T3 (es)	2002-09-16	Derivados de androsteno.
ATE263571T1 (de)	2004-04-15	Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
ATE336997T1 (de)	2006-09-15	Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
NO166939C (no)	1991-09-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
DE69635670D1 (de)	2006-02-02	Threitol-buttersäureester-enthaltende zusammensetzungen und ihre verwendung
ATE311191T1 (de)	2005-12-15	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE238805T1 (de)	2003-05-15	Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
ATE253117T1 (de)	2003-11-15	Adenovirus e4 proteine für induktion von zelltod
DE69939075D1 (de)	2008-08-21	Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
ITRM930365A0 (it)	1993-06-02	Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee.
ATE90563T1 (de)	1993-07-15	Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
ATE316379T1 (de)	2006-02-15	Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
TR200100897T2 (tr)	2001-10-22	Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
DE69927260D1 (de)	2005-10-20	Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
ATE5256T1 (de)	1983-11-15	Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
FI891210A7 (fi)	1989-03-14	Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet
Kadam et al.	2019	Treatment of gingival recession defect using human umbilical cord mesenchymal stem cells cultured on PCL based bone regenerating scaffold: a randomized controlled clinical study
NO890801D0 (no)	1989-02-24	Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.
ES2060440T3 (es)	1994-11-16	Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.